 By Brian Marckx, CFA NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT When Aethlon Medical NASDAQ:AEMD reported fiscal Q1 2020 financial results in August, management noted that they anticipated imminent filing of an Investigational Device Exemption IDE seeking approval to initiate U.S.-based clinical studies for their Hemopurifier device in cancer patients. Not only did that filing 